(lp0
S"The 3 Most Important Numbers for Exelixis, Inc. Motley Fool - Mar 14, 2017 Exelixis  boasts several numbers that make its shareholders smile. The biotech's stock has soared more than 430% over the past 12 months."
p1
aS"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited Motley Fool - Mar 1, 2017 Exelixis  reported fourth-quarter earnings on Monday showing solid growth in sales of Cabometyx. The biotech reported a profit for the quarter, but there were some extenuating circumstances that helped push Exelixis into the black.Company Update : Exelixis, Inc. Announces Clinical Trial ... - Smarter AnalystExelixis Announces Webcasts of Investor Conference Presentations in March - Yahoo Finance"
p2
aS'Exelixis Inc Risk Points versus Health Care CML News - 13 hours ago This is a scatter plot analysis of the critical risk points from the option market for Exelixis Inc  compared to its own past and the Health Care ETF.'
p3
aS'3 Factors That Drove Exelixis, Inc. Higher By 19% in February Motley Fool - Mar 7, 2017 Shares of Exelixis , a biopharmaceutical company focused on the development of medicines for the treatment of cancer, surged 19% in February, according to data from S&amp;P Global Market Intelligence.'
p4
aS"Form 4 EXELIXIS, INC. For: Mar 20 Filed by: FELDBAUM CARL B StreetInsider.com - Mar 21, 2017 Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite."
p5
aS'Market View: Checking on the Technicals for Exelixis, Inc.  Rives Journal - 15 hours ago Looking at shares of Exelixis, Inc. , the company has an EV  of 6134505. Enterprise Value is a measure of the total value of a specific company.'
p6
aS"Stock Showing Surging Activity: Exelixis, Inc.  HugoPress - 17 hours ago Oppenheimer Initiates Coverage On Exelixis, Inc. 's stock to Perform with no specific Price Target. This rating was issued on 3/16/17."
p7
aS'Buy, Sell or Hold? Analysts Approach: Vonage Holdings Corp. , Exelixis ... The USA Commerce - Mar 21, 2017 While trading at volume below than average, Exelixis, Inc.  previous 52-week high was $23.49 and moved up 469.51% over the same period, trading at a volume of 3.15 million.'
p8
aS'Exelixis, Inc.  Receives FDA Orphan Drug Designation for the Treatment ... Smarter Analyst - Mar 6, 2017 Exelixis, Inc.  announced that the FDA has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma .Hot Stock to Watch: Exelixis, Inc.  - HugoPress'
p9
aS"Zacks Provided 1.57 Rating to Exelixis, Inc.  The Newburgh Press - 16 hours ago Considering the performance, Exelixis, Inc. 's shares have the potential to reach a high EPS of 0.01 per share, and a low EPS of -0.05 per share in the current quarter."
p10
a.